Cargando…

Assessment of Liver Fibrosis: Noninvasive Means

Liver biopsy, owing to its limitations and risks, is an imperfect gold standard for assessing the severity of the most frequent chronic liver diseases chronic hepatitis C (HCV), B (HBV) non alcoholic (NAFLD) and alcoholic (ALD) fatty liver diseases. This review summarizes the advantages and the limi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poynard, Thierry, Morra, Rachel, Ingiliz, Patrick, Imbert-Bismut, Françoise, Thabut, Dominique, Messous, Djamila, Munteanu, Mona, Massard, Julien, Benhamou, Yves, Ratziu, Vlad
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2008
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702928/ https://www.ncbi.nlm.nih.gov/pubmed/19568532 http://dx.doi.org/10.4103/1319-3767.43273

Ejemplares similares

Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
por: Poynard, Thierry, et al.
Publicado: (2008)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
por: Poynard, Thierry, et al.
Publicado: (2011)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Hirsch Index and Truth Survival in Clinical Research
por: Poynard, Thierry, et al.
Publicado: (2010)

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2005)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
por: Poynard, Thierry, et al.
Publicado: (2016)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
por: Poynard, Thierry, et al.
Publicado: (2023)

Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
por: M'Kada, Helmi, et al.
Publicado: (2012)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
por: Prodanovic, Hélène, et al.
Publicado: (2007)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
por: Poynard, Thierry, et al.
Publicado: (2021)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
por: Houot, M., et al.
Publicado: (2015)

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies
por: Gosalia, Dhaval, et al.
Publicado: (2022)

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
por: Poynard, Thierry, et al.
Publicado: (2020)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Noninvasive Methods to Evaluate Liver Fibrosis in Chronic HCV Infection
por: El-Shabrawi, Mortada Hassan, et al.
Publicado: (2011)

Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing
por: About, Frédégonde, et al.
Publicado: (2019)

Multimodal monitoring intracranial pressure by invasive and noninvasive means
por: de Moraes, Fabiano Moulin, et al.
Publicado: (2023)

Influence of Expert-Dependent Variability over the Performance of Noninvasive Fibrosis Assessment in Patients with Chronic Hepatitis C by Means of Texture Analysis
por: Vicas, Cristian, et al.
Publicado: (2012)

Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis
por: Hoffmann, Céline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf6lkja3vhc2rd4hvvvffg1as7